NASDAQ : SRRK
Scholar Rock Holding Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 43.9 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 5.35B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.29B |
| Enterprise Value | 5.00B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 121.79M |
| Shares Outstanding | 121.79M |
| Shares Change (YoY) | +26.67% |
| Shares Change (QoQ) | +2.62% |
| Owned by Insiders (%) | 1.00% |
| Owned by Institutions (%) | 104.68% |
| Float | 103.88M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 138.12 |
| PB Ratio | 21.03 |
| P/TBV Ratio | 21.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.02 |
| Quick Ratio | 6.84 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -38.02 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -167.77% |
| Return on Assets (ROA) | -58.82% |
| Return on Invested Capital (ROIC) | -67.51% |
| Return on Capital Employed (ROCE) | -90.04% |
| Weighted Average Cost of Capital (WACC) | 7.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.41M |
| Employee Count | 289 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +49.98% |
| 50-Day Moving Average | 48.47 |
| 200-Day Moving Average | 48.21 |
| Relative Strength Index (RSI) | 49.24 |
| Average Volume (20 Days) | 1,839,530 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 22.18M |
| Short Previous Month | 22.72M |
| Short % of Shares Out | 18.21% |
| Short % of Float | 21.35% |
| Short Ratio (days to cover) | 9.77 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -207.41M |
| Operating Income | -406.36M |
| Pretax Income | -408.59M |
| Net Income | -408.59M |
| EBITDA | -404.88M |
| EBIT | -406.36M |
| Earnings Per Share (EPS) | -$3.36 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 492.09M |
| Total Debt | 203.83M |
| Net Cash | 288.26M |
| Net Cash Per Share | $2.37 |
| Equity (Book Value) | 253.78M |
| Book Value Per Share | 2.09 |
| Working Capital | 434.94M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -296.83M |
| Capital Expenditures | -185,000 |
| Depreciation & Amortization | 1.48M |
| Net Borrowing | 144.66M |
| Free Cash Flow | -297.01M |
| FCF Per Share | -$2.44 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.67% |
| Shareholder Yield | -26.67% |
| Earnings Yield | -7.74% |
| FCF Yield | -5.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $70.44 |
| Price Target Difference | 62.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |